Richard Pilnik wordt voorzitter van raad van bestuur Chiltern
LONDON & WILMINGTON, N.C.–(BUSINESS WIRE)– Chiltern, een toonaangevend internationaal bedrijf in klinisch onderzoek, heeft bekendgemaakt dat Richard Pilnik is benoemd tot voorzitter van de raad van bestuur. Pilnik trad in 2015 toe tot de raad van bestuur van Chiltern en droeg in grote mate bij aan de strategie en toekomstige koers van het bedrijf. Pilnik vervangt Nick Thornton, de huidige voorzitter.
Pilnik geldt binnen de sector als veteraan met belangrijke ervaring in de mondiale biofarmacie, die zich uitstrekt over Azië, Latijns-Amerika en de Verenigde Staten. Voordat hij voor Chiltern aan de slag ging, werkte Pilnik als uitvoerend vicepresident van Quintiles, waar hij ook president was van de divisie Commercial Solutions. Uit hoofde van deze functie gaf hij leiding aan de grootste internationale dienstverlener voor samenwerking en uitbesteding binnen de biofarmacie, met verantwoordelijkheden voor meer dan 7000 werknemers. In deze periode zorgde hij voor recordverkopen en -winsten en creëerde hij openstaande posten met een waarde van 1 miljard dollar, bestaande uit contracten met bedrijven in biofarmacie, medische apparatuur, diagnostiek en medische zorg.
Richard Pilnik Transitions from Director to Chairman of Chiltern |
|||||
|
LONDON & WILMINGTON, N.C.–(BUSINESS WIRE)– Chiltern, a leading global clinical research organization, announces that Richard Pilnik has been named chairman. In 2015, he joined the Chiltern board of directors and has made significant contributions to the company’s strategy and future direction. Pilnik replaces Nick Thornton, the current chairman.Pilnik is an industry veteran with significant experience in the global biopharmaceutical market throughout Asia, Europe, Latin America and the United States. Prior to joining Chiltern, Pilnik served as an executive vice president at Quintiles and president of its Commercial Solutions division. In this role, he led the largest worldwide provider of biopharmaceutical commercial partnerships and outsourcing services and had management responsibilities for more than 7,000 employees. During his tenure, he produced record sales and profits and created a contract backlog of more than $1 billion with companies in biopharmaceuticals, medical devices, diagnostics and health care services.
Pilnik also held several positions at Eli Lilly and Company including group vice president and chief marketing officer; president, Europe, Middle East and Africa; and area vice president of Latin America and Canada. “On behalf of Chiltern’s senior executive team and staff, as well as the investors and board of directors, I look forward to continuing to work with Rich in his new position as chairman,” said Jim Esinhart, CEO of Chiltern. “I would also like to thank Nick Thornton for his exceptional contribution to Chiltern over the past 10 years. Chiltern is the leader in the mid-tier CRO sector, and we will continue to deliver outstanding service to our clients and provide clinical solutions across a wide range of specialty areas and engagement models for the biopharmaceutical and medical device industries.” About Chiltern Chiltern, a global contract research organization, is the leading mid-sized provider of clinical solutions in a variety of specialty areas and engagement models for biopharmaceutical and medical device industries. Chiltern’s team of more than 4,200, located across 47 countries, provides comprehensive Clinical Development, Medical & Scientific Affairs, Data & Analysis, Pharmacovigilance, Strategic Regulatory and Clinical Supplies services using a collaborative approach to maximize efficiency and minimize delays. Visit Chiltern.com to learn more about how Chiltern is Designed Around You ®. View source version on businesswire.com: http://www.businesswire.com/news/home/20160601005302/en/ Contacts SCORR Marketing |
|||||